International
GLP-1 prices: US vs the rest of the world
US patients pay 4-7× what the same drug costs in single-payer health systems. The difference reflects negotiation power, not manufacturing cost. Here is the 2026 picture plus the legal framing around importation.
Price comparison (28-day supply)
| Drug | US | UK | Canada | EU | AU |
|---|---|---|---|---|---|
| Wegovy 2.4 mg | $1,199 | £199 (~$255) | C$415 (~$305) | €140-280 (~$155-310) | AU$555 (~$365) |
| Zepbound 15 mg | $1,059 | N/A | C$870 (~$640) | €430 (~$475) (where avail.) | AU$610 (~$400) |
| Ozempic 1.0 mg | $968 | £93 (~$120) | C$280 (~$205) | €105 (~$115) | AU$133 PBS subsidized |
| Mounjaro 5 mg | $1,135 | £175 (~$225) | C$760 (~$560) | €155 (~$170) | AU$420 (~$275) |
USD conversions at May 2026 rates. Subsidized prices vary by national health system (NHS, PBS, public coverage). Cash prices shown — most non-US patients pay nothing or small co-pay.
Personal importation — the legal reality
The FDA's Personal Importation Policy is discretionary. Individual patients importing a 90-day supply for personal use are generally not prosecuted, but the drugs are technically unapproved imports. Customs may seize at the border; legal recourse is limited.
Practical recommendation: pursue US-domestic cost reduction first — manufacturer savings cards, compounded semaglutide via 503A pharmacies, insurance appeals, HSA/FSA reimbursement. Importation should be a last resort, with full understanding of seizure risk and lack of pharmacy-grade verification on imported supply.